<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Toward Valid Generative Clinical Trial Data with Survival Endpoints - Health AI Hub</title>
    <meta name="description" content="This paper introduces a novel Variational Autoencoder (VAE) designed to generate valid synthetic clinical trial data, specifically focusing on complex time-to-e">
    <link rel="icon" type="image/svg+xml" href="../favicon.svg">
    <link rel="icon" type="image/png" sizes="32x32" href="../favicon-32x32.png">
    <link rel="icon" type="image/png" sizes="16x16" href="../favicon-16x16.png">
    <link rel="stylesheet" href="../styles.css">
</head>
<body>
    <header>
        <div class="container">
            <div class="breadcrumb">
                <a href="../index.html">‚Üê Back to all papers</a>
                <a href="../index.html" class="home-btn">üè† Home</a>
            </div>
        </div>
    </header>

    <main class="container paper-detail">
        <article>
            <h1>Toward Valid Generative Clinical Trial Data with Survival Endpoints</h1>

            <div class="paper-metadata">
                <div class="meta-row">
                    <strong>arXiv ID:</strong> <a href="http://arxiv.org/abs/2511.16551v1" target="_blank">2511.16551v1</a>
                </div>
                <div class="meta-row">
                    <strong>Published:</strong> 2025-11-20
                </div>
                <div class="meta-row">
                    <strong>Authors:</strong> Perrine Chassat, Van Tuan Nguyen, Lucas Ducrot, Emilie Lanoy, Agathe Guilloux
                </div>
                <div class="meta-row">
                    <strong>Categories:</strong> cs.LG, stat.AP, stat.ME, stat.ML
                </div>
                <div class="meta-row">
                    <strong>Relevance Score:</strong> 0.95 / 1.00
                </div>
            </div>

            <div class="action-buttons">
                <a href="http://arxiv.org/abs/2511.16551v1" target="_blank" class="btn btn-primary">View on arXiv</a>
                <a href="https://arxiv.org/pdf/2511.16551v1" target="_blank" class="btn btn-primary">Download PDF</a>
            </div>

            <section class="paper-section">
                <h2>Summary</h2>
                <p class="summary-text">This paper introduces a novel Variational Autoencoder (VAE) designed to generate valid synthetic clinical trial data, specifically focusing on complex time-to-event (survival) outcomes alongside mixed-type covariates. Addressing limitations of existing generative AI methods like GANs, the VAE operates within a unified latent framework, does not assume independent censoring, and outperforms baselines in fidelity, utility, and privacy for scenarios like data sharing and control-arm augmentation. While revealing systematic miscalibration in generated survival data, the authors propose a post-generation selection procedure that significantly improves calibration, marking a step forward in generative survival modeling for clinical research.</p>
            </section>

            <section class="paper-section">
                <h2>Medical Relevance</h2>
                <p>This research is highly relevant to medicine and health as it offers a solution to make clinical trials, especially in areas like oncology and rare diseases, more efficient, cost-effective, and less dependent on large, hard-to-recruit patient populations. By generating high-fidelity synthetic control arms, it can accelerate drug development and facilitate data sharing while maintaining privacy.</p>
            </section>

            
            <section class="paper-section">
                <h2>AI Health Application</h2>
                <p>The AI application is the generation of synthetic clinical trial data, specifically control arms and time-to-event (survival) outcomes, using generative AI models (VAEs). This aims to improve the efficiency, cost-effectiveness, and data privacy of medical clinical trials, facilitate data sharing, and address issues like patient recruitment and group imbalances in medical research.</p>
            </section>
            

            <section class="paper-section">
                <h2>Key Points</h2>
                <ul class="key-points">
                    
                    <li>Clinical trials, particularly in oncology and rare diseases, face severe challenges including fragmented populations, slow enrollment, and high costs, driving interest in synthetic control arms.</li>
                    
                    <li>The core technical challenge addressed is the accurate generation of time-to-event (survival) outcomes, which are primary endpoints but are difficult to model under censoring and small sample sizes.</li>
                    
                    <li>The authors propose a Variational Autoencoder (VAE) that jointly generates mixed-type covariates and survival outcomes within a unified latent variable framework.</li>
                    
                    <li>A key innovation of the VAE is its ability to model survival outcomes without assuming independent censoring, a common and often unrealistic assumption in other generative approaches (e.g., GANs).</li>
                    
                    <li>The model was evaluated in two realistic scenarios: (i) data sharing under privacy constraints, where synthetic controls substitute for original data, and (ii) control-arm augmentation to mitigate imbalances between treatment groups.</li>
                    
                    <li>The VAE consistently outperforms GAN baselines across fidelity (how similar synthetic data is to real), utility (how well synthetic data supports downstream analysis), and privacy metrics.</li>
                    
                    <li>A critical finding is that generated survival data, even from their improved VAE, exhibits systematic miscalibration of type I error and statistical power, highlighting a significant challenge for generative survival modeling.</li>
                    
                    <li>A post-generation selection procedure is proposed and demonstrated to effectively improve the calibration of type I error and power, suggesting a practical mitigation strategy.</li>
                    
                </ul>
            </section>

            <div class="two-column">
                <section class="paper-section">
                    <h2>Methodology</h2>
                    <p>The core methodology involves developing a Variational Autoencoder (VAE) specifically designed for the joint generation of mixed-type covariates and time-to-event (survival) outcomes. This VAE operates within a unified latent variable framework and does not assume independent censoring. The model's performance was evaluated against GAN-based baselines across synthetic and real clinical trial datasets. Evaluation metrics focused on fidelity, utility, and privacy in two specific use cases: data sharing (synthetic data as a proxy) and control-arm augmentation (balancing treatment groups). A post-generation selection procedure was also developed and assessed to improve the statistical calibration of the generated survival data.</p>
                </section>

                <section class="paper-section">
                    <h2>Key Findings</h2>
                    <p>The VAE model significantly outperforms existing GAN-based generative methods in fidelity, utility, and privacy for generating complex clinical trial data, including survival endpoints. However, a critical discovery was the systematic miscalibration of type I error and statistical power within the generated survival data. This miscalibration, if unaddressed, could lead to incorrect conclusions from synthetic trials. A subsequent post-generation selection procedure was shown to successfully improve this calibration.</p>
                </section>
            </div>

            <section class="paper-section">
                <h2>Clinical Impact</h2>
                <p>This work has the potential to profoundly impact clinical trials by enabling faster, more cost-effective, and ethical drug development, particularly for conditions with small or fragmented patient populations (e.g., rare diseases, specific cancer subtypes). It can facilitate the use of synthetic control arms, reducing the need for large patient cohorts, accelerating enrollment, and lowering trial costs. It also offers a pathway for privacy-preserving data sharing and can improve trial design by allowing for augmentation of control groups to balance baseline characteristics.</p>
            </section>

            
            <section class="paper-section">
                <h2>Limitations</h2>
                <p>Existing generative approaches (GANs) are noted as data-hungry, unstable, and reliant on strong assumptions like independent censoring. While the proposed VAE addresses some of these, a significant limitation revealed by the study is the systematic miscalibration of type I error and power in the generated survival outcomes, even with the advanced VAE. This necessitates a post-generation selection procedure to achieve reliable statistical properties, indicating that perfectly calibrated, raw synthetic survival data remains an open challenge.</p>
            </section>
            

            
            <section class="paper-section">
                <h2>Future Directions</h2>
                <p>The paper explicitly highlights "open challenges for generative survival modeling," implying further research is needed to inherently improve the statistical calibration of generated time-to-event data without requiring post-processing. Future work could focus on developing generative models that are intrinsically more robust to miscalibration, exploring different architectures or loss functions tailored to survival statistics, and further validating these methods across a wider range of clinical trial designs and disease contexts.</p>
            </section>
            

            <section class="paper-section">
                <h2>Medical Domains</h2>
                <div class="tags">
                    
                    <span class="tag">Oncology</span>
                    
                    <span class="tag">Rare Diseases</span>
                    
                    <span class="tag">Clinical Trial Design</span>
                    
                    <span class="tag">Drug Development</span>
                    
                    <span class="tag">Medical Statistics</span>
                    
                    <span class="tag">Precision Medicine</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Keywords</h2>
                <div class="tags">
                    
                    <span class="tag tag-keyword">Generative AI</span>
                    
                    <span class="tag tag-keyword">Clinical Trials</span>
                    
                    <span class="tag tag-keyword">Synthetic Data</span>
                    
                    <span class="tag tag-keyword">Survival Analysis</span>
                    
                    <span class="tag tag-keyword">Variational Autoencoder</span>
                    
                    <span class="tag tag-keyword">Time-to-Event</span>
                    
                    <span class="tag tag-keyword">Oncology</span>
                    
                    <span class="tag tag-keyword">Rare Diseases</span>
                    
                    <span class="tag tag-keyword">Censoring</span>
                    
                    <span class="tag tag-keyword">Data Utility</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Abstract</h2>
                <p class="abstract">Clinical trials face mounting challenges: fragmented patient populations, slow enrollment, and unsustainable costs, particularly for late phase trials in oncology and rare diseases. While external control arms built from real-world data have been explored, a promising alternative is the generation of synthetic control arms using generative AI. A central challenge is the generation of time-to-event outcomes, which constitute primary endpoints in oncology and rare disease trials, but are difficult to model under censoring and small sample sizes. Existing generative approaches, largely GAN-based, are data-hungry, unstable, and rely on strong assumptions such as independent censoring. We introduce a variational autoencoder (VAE) that jointly generates mixed-type covariates and survival outcomes within a unified latent variable framework, without assuming independent censoring. Across synthetic and real trial datasets, we evaluate our model in two realistic scenarios: (i) data sharing under privacy constraints, where synthetic controls substitute for original data, and (ii) control-arm augmentation, where synthetic patients mitigate imbalances between treated and control groups. Our method outperforms GAN baselines on fidelity, utility, and privacy metrics, while revealing systematic miscalibration of type I error and power. We propose a post-generation selection procedure that improves calibration, highlighting both progress and open challenges for generative survival modeling.</p>
            </section>

            
            <section class="paper-section">
                <h2>Comments</h2>
                <p>P. Chassat and V.T. Nguyen contributed equally to this work</p>
            </section>
            

            
            <section class="paper-section">
                <h2>Journal Reference</h2>
                <p>Machine Learning for Health (ML4H) 2025</p>
            </section>
            
        </article>
    </main>

    <footer class="container">
        <p><a href="../index.html">‚Üê Back to all papers</a></p>
    </footer>
</body>
</html>